ERBB2 and neoplasm: Although trastuzumab was demonstrated to inhibit HER2 mediated tumor growth, recent studies have shown that trastuzumab does not completely abolish HER2 phosphorylation or its kinase activity [9, 21, 22], and the contribution of HER2 phosphorylation to trastuzumab resistance was not unambiguously elucidated.